Klerimed Adverse Reactions

The most frequent and common adverse reactions related to clarithromycin therapy for both adult and pediatric populations are abdominal pain, diarrhea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics.
There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections.
Table 2 displays adverse reactions reported in clinical trials and from post-marketing experience with Klerimed immediate release, granules for oral suspension, IV and modified-release (MR).
The reactions considered at least possibly related to clarithromycin are displayed by system organ class and frequency using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed. (See Table 2.)

Click on icon to see table/diagram/image

There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency, some with a fatal outcome. Deaths have been reported in some such patients (see Contraindications, Precautions and Interactions).
Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.
Immunocompromised Patients: In acquired immunodeficiency syndrome (AIDS) and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of human immunodeficiency virus (HIV) disease or intercurrent illness.
In adult patients, the most frequently reported adverse events by patients treated with total daily doses of clarithromycin 1,000 mg were: Nausea, vomiting, taste perversion, abdominal pain, diarrhea, rash, flatulence, headache, constipation, hearing disturbance, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) elevations. Additional low-frequency events included dyspnea, insomnia and dry mouth.
In these immunocompromised patients, evaluations of laboratory values were made by analyzing those values outside the seriously abnormal level (ie, the extreme high or low limit) for the specified test. On the basis of this criteria, about 2-3% of these patients who received clarithromycin 1000 mg daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients also had elevated blood urea nitrogen levels.